|Bid||124.06 x 100|
|Ask||124.13 x 100|
|Day's Range||121.87 - 124.47|
|52 Week Range||77.58 - 153.15|
|PE Ratio (TTM)||-220.37|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
Incyte's Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.
Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.